Fig. 4

Inhibiting Th2-mediated immunity reshapes the immune landscape in the TME. A, B Representative quantification of myeloid-derived suppressor cell (MDSC), tumor-associated macrophage (TAM), and regulatory T cell (Treg) of CD45⁺ live cells in EO771 (A) and 4T1 (B) tumors (n = 5, two-way ANOVA). C T-SNE plot of TILs overlaid with color-coded clusters in EO771 tumors. D T-SNE plot of tumor-infiltrating leukocytes overlaid with color-coded clusters from vehicle-treated or IPD-treated mice. E Frequency of clusters of indicated immune cell subsets from vehicle-treated and IPD-treated mice (n = 5, t-test). F Macrophage-associated density t-SNE plots and quantification of an equal number of CD45⁺ tumor-infiltrating leukocytes in vehicle-treated versus IPD-treated mice. G, H Relative MHC II:CD206 ratio of TAMs in EO771 and 4T1 tumors from vehicle-treated versus IPD-treated mice (n = 5, t test). Mean ± SEM; * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant